RUNX1在肺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2022.06.016

Abstract

Abstract: Runt-related transcription factor 1(RUNX1),a member of the RUNX family,is one of the key regulatory proteins in vertebrates.RUNX1 is involved in embryonic development,haematopoiesis,angiogenesis,tumorigenesis and immune response.In the past decades,the research mainly focused on the mechanism of RUNX1 in acute leukaemia,and there were few reports on the role of RUNX1 in the pathological process of lung cancer.The latest research shows that RUNX1 is highly expressed in the mesenchymal and epithelial cells of the human development and postnatal lung,and is closely related to the occurrence and progression of lung cancer.This article reviews the research progress of RUNX1 in the occurrence and progress of lung cancer.

Key words: Lung cancer, Runt-related transcription factor 1, Research progress

CLC Number:

R734.2

CHEN Junhui, LIU Siyu, HE Changjun. Research progress of RUNX1 in lung cancer[J]. Journal of Practical Oncology, 2022, 36(6): 576-579.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.06.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I6/576

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Bae SC,Yamaguchi-Iwai Y,Ogawa E,et al.Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene,AML1[J].Oncogene,1993,8(3):809-814.
3 Ogawa E,Maruyama M,Kagoshima H,et al.PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene[J].Proc Natl Acad Sci U S A,1993,90(14):6859-6863.
4 Yokota A,Huo L,Lan F,et al.The clinical,molecular,and mechanistic basis of RUNX1 mutations identified in hematological malignancies[J].Mol Cells,2020,43(2):145-152.
5 Fritz AJ,Hong D,Boyd J,et al.RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells[J].J Cell Physiol,2020,235(10):7261-7272.
6 Huang J,Hagberg Thulin M,Damber JE,et al.The roles of RUNX2 and osteoclasts in regulating expression of steroidogenic enzymes in castration-resistant prostate cancer cells[J].Mol Cell Endocrinolo,2021,535:111380.
7 Hideura E,Suehiro Y,Nishikawa J,et al.Blood free-circulating DNA testing of methylated RUNX3 is useful for diagnosing early gastric cancer[J].Cancers,2020,12(4):2292-2302.
8 Song J,Liu Y,Wang T,et al.MiR-17-5p promotes cellular proliferation and invasiveness by targeting RUNX3 in gastric cancer[J].Biomed Pharmacother,2020,128:110246.
9 Han J,Yang Z,Zhao S,et al.Circ_0027599 elevates RUNX1 expression via sponging miR-21-5p on gastric cancer progression[J].Eur J Clin Invest,2021,51(11):e13592.
10 Miyoshi H,Ohira M,Shimizu K,et al.Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia[J].Nucleic Acids Res,1995,23(14):2762-2769.
11 Ogawa E,Maruyama M,Kagoshima H,et al.PEBP2/PEA2 represents a family of transcription factors homologous to the products of the drosophila runt gene and the human AML1 gene[J].Proc Natl Acad Sci U S A,1993,90(14):6859-6863.
12 Okuda T,van Deursen J,Hiebert SW,et al.AML1,the target of multiple chromosomal translocations in human leukemia,is essential for normal fetal liver hematopoiesis[J].Cell,1996,84(2):321-330.
13 Wang Q,Stacy T,Binder M,et al.Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis[J].Proc Natl Acad Sci U S A,1996,93(8):3444-3449.
14 Thomas AL,Marsman J,Antony J,et al.Transcriptional regulation of RUNX1:An informatics analysis[J].Genes(Basel),2021,12(8):1175-1192.
15 Kim Y,Lee BB,Kim D,et al.Clinicopathological significance of RUNX1 in non-small cell lung cancer[J].J Clin Med,2020,9(6):1694.
16 Tang X,Sun L,Wang G,et al.RUNX1:a regulator of NF-kB signaling in pulmonary diseases[J].Curr Protein Pept Sci,2018,19(2):172-178.
17 Haley KJ,Lasky-Su J,Manoli SE,et al.RUNX transcription factors:association with pediatric asthma and modulated by maternal smoking[J].Am J Physiol Lung Cell Mol Physiol,2011,301(5):1693-2701.
18 Ishikawa R,Amano Y,Kawakami M,et al.The chimeric transcript RUNX1-GLRX5:a biomarker for good postoperative prognosis in stage IA non-small-cell lung cancer[J].Jpn J Clin Oncol,2016,46(2):185-189.
19 Chen Y,Zhang L,Liu L,et al.Rasip1 is a RUNX1 target gene and promotes migration of NSCLC cells[J].Cancer Manag Res,2018,10:4537-4552.
20 He C,Bai X,Li Y,et al.Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5[J].Cell Cycle,2019,18(23):3404-3419.
21 Ramsey J,Butnor K,Peng Z,et al.Loss of RUNX1 is associated with aggressive lung adenocarcinomas[J].J Cell Physiol,2018,233(4):3487-3497.
22 Hosoi H,Niibori-Nambu A,Nah G,et al.Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines[J].Gene,2021,774:145421.
23 Takayama K,Suzuki T,Tsutsumi S.RUNX1 an androgen-and EZH2-regulated gene,has di erential roles in AR-dependent and-independent prostate cancer[J].Oncotarget,2015,6,2263-2276.
24 Hong D,Messier TL,Tye CE.Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition[J].Oncotarget,2017,8,17610-17627.
25 Hong D,Fritz AJ,Finstad KH.Suppression of breast cancer stem cells and tumor growth by the RUNX1 transcription factor[J].Mol Cancer Res,2018,16,1952-1964.

[1]	XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome [J]. Journal of Practical Oncology, 2022, 36(6): 544-550.
[2]	WU Ruiyue, ZHU Kaili, YANG Jingru, LING Xiaoling. Clinical research progress of breast cancer with low HER2 expression [J]. Journal of Practical Oncology, 2022, 36(6): 570-575.
[3]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[4]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.
[5]	LI Xinlin, ZHOU Jinyi, HAN Renqiang, CAI Bo, XU Hong, HAN Yingying. Analysis of epidemiological characteristics of lung cancer in Nantong City from 2013 to 2017 [J]. Journal of Practical Oncology, 2022, 36(4): 304-309.
[6]	SUN Weiling, ZHANG Minghui, WU Huaxing, ZHAO Yanbin. Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 316-322.
[7]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[8]	ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC [J]. Journal of Practical Oncology, 2022, 36(3): 214-219.
[9]	XIAO Haifan, YAN Shipeng, LI Jigang, SHI Zhaohui, ZOU Yanhua, XU Kekui, LIAO Xianzhen. Screening results and compliance analysis of low-dose spiral CT for lung cancer in Hunan from 2017 to 2018 [J]. Journal of Practical Oncology, 2022, 36(2): 99-104.
[10]	ZHANG Mengru, CAO Dedong, GE Wei. Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(1): 20-25.
[11]	LUO Wen, JIA Li, ZHANG Jiawen, WANG Dongjie, KONG Yingjun. The effects of circRNA MYO1C on lung cancer cell autophagy and cancer stem cell differentiation [J]. Journal of Practical Oncology, 2021, 35(6): 500-505.
[12]	ZHAO Haoran, LI Man, ZHANG Yubao. Research progress of hepatocellular carcinoma-related RNA binding protein [J]. Journal of Practical Oncology, 2021, 35(6): 576-579.
[13]	WU Changshuai, ZHANG Baohui, GAO Zhenglian, ZHANG Xiaowang, WANG Kun. Research progress in anti-tumor effect of propofol and its molecular mechanism in lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 480-484.
[14]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.
[15]	REN Siying, CHEN Yang, SHI Qingping, ZHU Yunfang, WEN Hongmei. Characteristics of lung cancer incidence and mortality from 2011 to 2016 in the cancer registration areas of Yunnan province and its time trend [J]. Journal of Practical Oncology, 2021, 35(4): 332-338.

Research progress of RUNX1 in lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments